Pancreatic neuroendocrine and carcinoid tumors: What's new, what's old, and what's different?

Current Oncology Reports

Volumn 14, Issue 3, 2012, Pages 249-256

  Reidy Lagunes, Diane ^a,b,c   Thornton, Raymond ^b,c  

^a Gastrointestinal Oncology Service   (United States)

^b WEILL CORNELL MEDICAL COLLEGE   (United States)

^c MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

Bland embolization; Carcinoid; Embolization; Everolimus; Gastrointestinal cancers; Neuroendocrine tumors; Pancreatic NETs; Streptozocin; Sunitinib; Temozolomide; Yttrium 90 spheres

Indexed keywords

ANGIOPEPTIN; ANTINEOPLASTIC AGENT; BEVACIZUMAB; CAPECITABINE; CHLOROZOTOCIN; CYCLOPHOSPHAMIDE; DACARBAZINE; DOXORUBICIN; EVEROLIMUS; FLUOROURACIL; FOLINIC ACID; INDIUM 111; INTERFERON; LANREOTIDE Y 90; LUTETIUM 177; OCTREOTIDE; OCTREOTIDE LU 177; OXALIPLATIN; PEGINTERFERON ALPHA2B; PLACEBO; PLATINUM COMPLEX; SOMATOSTATIN DERIVATIVE; STREPTOZOCIN; SUNITINIB; TEMOZOLOMIDE; TEMSIROLIMUS; THALIDOMIDE; UNCLASSIFIED DRUG; YTTRIUM 90; ANGIOGENESIS INHIBITOR; DRUG DERIVATIVE; IMMUNOSUPPRESSIVE AGENT; INDOLE DERIVATIVE; MTOR PROTEIN, HUMAN; PYRROLE DERIVATIVE; RAPAMYCIN; TARGET OF RAPAMYCIN KINASE; VASCULOTROPIN; YTTRIUM;

ADVANCED CANCER; ANEMIA; ANOREXIA; ARTICLE; ARTIFICIAL EMBOLISM; ASTHENIA; BLAND EMBOLIZATION; CANCER CLASSIFICATION; CANCER GENETICS; CANCER GRADING; CANCER GROWTH; CANCER RADIOTHERAPY; CANCER SURVIVAL; CARCINOID; CHEMOEMBOLIZATION; CHEMOTHERAPY INDUCED EMESIS; CYTOREDUCTIVE SURGERY; DIARRHEA; DRUG APPROVAL; DRUG EFFICACY; DRUG ERUPTION; DRUG SAFETY; DYSGEUSIA; EPISTAXIS; FATIGUE; FOOD AND DRUG ADMINISTRATION; GENE MUTATION; HAND FOOT SYNDROME; HISTOPATHOLOGY; HUMAN; HYPERGLYCEMIA; HYPERTENSION; HYPOGLYCEMIA; ISOTOPE LABELING; LEUKEMIA; LIVER METASTASIS; LIVER RESECTION; LIVER TOXICITY; LOW DRUG DOSE; LUNG CARCINOMA; LUNG SMALL CELL CANCER; LYMPHOCYTOPENIA; METASTASIS POTENTIAL; MUTATIONAL ANALYSIS; MYELODYSPLASTIC SYNDROME; NAUSEA; NEUROENDOCRINE TUMOR; NEUTROPENIA; NONHUMAN; OPPORTUNISTIC INFECTION; OVERALL SURVIVAL; PANCREATIC NEUROENDOCRINE TUMOR; PROGRESSION FREE SURVIVAL; PROSPECTIVE STUDY; RADIOFREQUENCY ABLATION; STOMATITIS; SURVIVAL RATE; SURVIVAL TIME; SYMPTOM; TREATMENT INDICATION; TREATMENT RESPONSE; UPPER RESPIRATORY TRACT INFECTION; DRUG ANTAGONISM; METHODOLOGY; MULTIMODALITY CANCER THERAPY; PANCREAS TUMOR; REVIEW;

ANGIOGENESIS INHIBITORS; ANTINEOPLASTIC AGENTS; CARCINOID TUMOR; COMBINED MODALITY THERAPY; DACARBAZINE; EMBOLIZATION, THERAPEUTIC; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INDOLES; NEUROENDOCRINE TUMORS; PANCREATIC NEOPLASMS; PYRROLES; SIROLIMUS; STREPTOZOCIN; TOR SERINE-THREONINE KINASES; VASCULAR ENDOTHELIAL GROWTH FACTORS; YTTRIUM RADIOISOTOPES;

EID: 84864025307     PISSN: 15233790     EISSN: 15346269     Source Type: Journal    
DOI: 10.1007/s11912-012-0232-1     Document Type: Article

References (60)

1. •• Yao JC, ShahMH, Ito T, et al. Everolimus for advanced pancreatic neuroendocrine tumors. N Engl J Med. 2011;364:514-23. This randomized controlled phase III study showed that everolimus improves progression-free survival when compared to placebo in patients with progressive pancreatic NETs and led to its FDA approval in 2011.
2. •• Raymond E, Dahan L, Raoul JL, et al. Sunitinib malate for the treatment of pancreatic neuroendocrine tumors. N Engl J Med. 2011;364:501-13. This randomized controlled phase III study showed that sunitinib improves progression-free survival when compared to placebo in patients with progressive pancreatic NETs and led to its FDA approval in 2011.
3. Ferrone C, Tang L, Tomplinson J, et al. Pancreatic neuroendocrine tumors: Can the WHO staging system be simplified. In: ASCO; 2007; Chicago; 2007. p. 15038.
4. Van Eeden S, Quadvlieg P, Babs G, et al. Classification of lowgrade neuroendocrine tumors of midgut and unknown origin. Hum Pathol. 2002;33:1126-32.
5. Rindi G, D'Adda T, Froio E, Fellegara G, Bordi C. Prognostic factors in gastrointestinal endocrine tumors. Endocr Pathol. 2007;18:145-9.
6. Moertel C, Kvols L, O'Connell M, Rubin J. Treatment of neuroendocrine carcinomas with combined etoposide and cisplatin: Evidence of major therapeutic activity in the anaplastic variants of these neoplasms. Cancer. 1991;68:227-32.
7. Strosberg JR, Cheema A, Weber J, Han G, Coppola D, Kvols LK. Prognostic validity of a novel American Joint Committee on Cancer Staging Classification for Pancreatic Neuroendocrine Tumors. J Clin Oncol 2011.
8. Jiao Y, Shi C, Edil BH, et al. DAXX/ATRX, MEN1, and mTOR pathway genes are frequently altered in pancreatic neuroendocrine tumors. Science. 2011;331:1199-203.
9. Delcore R, Friesen SR. Gastrointestinal neuroendocrine tumors. J Am Coll Surg. 1994;178:187-211.
10. Kwekkeboom DJ, de Herder WW, Kam BL, et al. Treatment with the radiolabeled somatostatin analog [177 Lu-DOTA 0, Tyr3] octreotate: Toxicity, efficacy, and survival. J Clin Oncol: Official J Am Soc Clin Oncol. 2008;26:2124-30.
11. Madoff DC, Gupta S, Ahrar K, Murthy R, Yao JC. Update on the management of neuroendocrine hepatic metastases. J Vasc Intervent Radiol: JVIR. 2006;17:1235-49. quiz 50.
12. Reidy DL, Tang LH, Saltz LB. Treatment of advanced disease in patients with well-differentiated neuroendocrine tumors. Nat Clin Pract Oncol. 2009;6:143-52.
13. Schurr P, Strate T, Rese K, et al. Aggressive surgery improves long-term survival in neuroendocrine pancreatic tumors: An institutional experience. Ann Surg. 2007;245:273-81.
14. Touzios J, Kiely J, Pitt S, et al. Neuroendocrine hepatic metastases: Does aggressive management improve survival? Ann Surg. 2005;241:776-83.
15. Sarmiento J, Heywood G, Rubin Jea. Surgical treatment of neuroendocrine metastases to the liver: A plea for resection to increase survival. J Am Coll Surg 2003;197.
16. Chamberlain R, Canes D, Brown K, et al. Hepatic neuroendocrine metastases: Does intervention affect outcome? J Am Coll Surg. 2000;190:432-45.
17. Ruszniewski P, Rougier P, Roche A, et al. Hepatic arterial chemoembolization in patients with liver metastases of endocrine tumors. A prospective phase II study in 24 patients. Cancer. 1993;71:2624-40.
18. Eriksson B, Larsson E, Skogseid B, et al. Liver embolizations of patients with malignant neuroendocrine gastrointestinal tumors. Cancer. 1998;83:2293-301.
19. Gupta S, Yao J, Ahrar K, et al. Hepatic Artery Embolization and chemoembolization for treatment of patients with metastatic carcinoid tumors: The MD Anderson Experience. Cancer. 2003;9:261-7.
20. Moertel C, Johnson C, McKusick M, et al. The management of patients with advanced carcinoid tumors and islet cell carcinomas. Ann Intern Med. 1994;120:302-9.
21. Kennedy AS, Dezarn WA, McNeillie P, et al. Radioembolization for unresectable neuroendocrine hepatic metastases using resin 90Y-microspheres: Early results in 148 patients. Am J Clin Oncol. 2008;31:271-9.
22. Rhee TK, Lewandowski RJ, Liu DM, et al. 90Y Radioembolization for metastatic neuroendocrine liver tumors: Preliminary results from a multi-institutional experience. Ann Surg. 2008;247:1029-35.
23. King J, Quinn R, Glenn DM, et al. Radioembolization with selective internal radiation microspheres for neuroendocrine liver metastases. Cancer. 2008;113:921-9.
24. Cao CQ, Yan TD, Bester L, Liauw W, Morris DL. Radioembolization with yttrium microspheres for neuroendocrine tumour liver metastases. Br J Surg. 2010;97:537-43.
25. Kraenzlin ME, Ch'ng JL, Wood SM, Carr DH, Bloom SR. Longterm treatment of a VIPoma with somatostatin analogue resulting in remission of symptoms and possible shrinkage of metastases. Gastroenterology. 1985;88:185-7.
26. Vezzosi D, Bennet A, Rochaix P, et al. Octreotide in insulinoma patients: Efficacy on hypoglycemia, relationships with Octreoscan scintigraphy and immunostaining with anti-sst2A and anti-sst5 antibodies. Eur J Endocrinol. 2005;152:757-67.
27. Rinke A, Muller HH, Schade-Brittinger C, et al. Placebocontrolled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: A report from the PROMID Study Group. J Clin Oncol. 2009;27:4656-63.
28. National Comprehensive Care Network Organizations, www. nccn.org; last accessioned Novemeber 21, 2011.
29. Couvelard A, O'Toole D, Turley H, et al. Microvascular density and hypoxia-inducible factor pathway in pancreatic endocrine tumours: Negative correlation of microvascular density and VEGF expression with tumour progression. Br J Cancer. 2005;92:94-101.
30. Kulke M, Lenz H, Meropol N, et al. Results of a phase II study with sunitinib malate (SU11248) in patients with advanced neuroendocrine tumours. Eur J Canc 2005;Suppl.
31. Kulke MH, Lenz HJ, Meropol NJ, et al. Activity of sunitinib in patients with advanced neuroendocrine tumors. J Clin Oncol. 2008;26:3403-10.
32. Duran I, Kortmansky J, Singh D, et al. A phase II clinical and pharmacodynamic study trial of temsirolimus in advanced neuroendocrine tumors. Br J Canc. 2006;95:1148-54.
33. Yao JC, Phan AT, Chang DZ, et al. Efficacy of RAD001 (everolimus) and octreotide LAR in advanced low-to intermediategrade neuroendocrine tumors: Results of a phase II study. J Clin Oncol. 2008;26:4311-8.
34. Terris B, Scoazec J, Rubbia L, et al. Expression of vascular endothelial growth factor in digestive tumours. Histopathology. 1998;32:133-8.
35. Phan A, Wang L, Xie K, et al. Association of VEGF expression with poor prognosis among patients with low-grade neuroendocrine carcinoma. In: Annual Meeting of American Society of Clinical Oncology; 2006; Atlanta; 2006.
36. Hurwitz H, Fehrenbacher L, Novotyn W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med. 2004;350:2335-42.
37. Kulke M, Stuart K, Earle C, et al. A phase II study of temozolomide and bevacizumab in patients with advanced neuroendocrine tumors. In: Proceedings ASCO 2006; Atlanta, GA; 2006.
38. Walderr C, Pless M, Maecke H, et al. The clinical value of [90YDOTA]-dPhe-Tyr-octreotide in the treatment of neuroendocrine tumours: A clinical phase II study. Ann Oncol. 2001;12:941-5.
39. Waldherr C, Pless M, Maecke H, et al. Tumor response and clinical benefit in neuroendocrine tumors after 7.4 GBq (90)Y-DOTATOC. J Nucl Med. 2002;43:610-6.
40. Virgolini I, Britton K, Buscombe J, et al. 111In-and 90Y-DOTALanreotide: Results and implications of the MAURITIUS trial. J Nucl Med. 2002;32:148-55.
41. Valkema R, Pauwels S, Kvols L, et al. Survival and response after peptide receptor radionuclide therapy with [90Y-DOTA0, Tyr3] octreotide in patients with advanced gastroenteropancreatic neuroendocrine tumors. Semin Nucl Med. 2006;36:147.
42. Kwekkeboom D, Wouter W, de Herder B, et al. Treatment with the radiolabeled somatostatin analog [177Lu-DOTA0, Tyr3]Octreotate: Toxicity, efficacy, and survival. J Clin Oncol. 2008;26:2124-30.
43. Kwekkeboom J, Teunissen J, Bakker WH. Treatment with the radiolabeled somatostatin analogue [177Lu-DOTA° Tyr3]octreotate in patients with gastro-entero-pancreatic (GEP) tumors. J Clin Oncol. 2005;23:2754-62.
44. Moertel CG, Lefkopoulo M, Lipsitz S, Hahn RG, Klaassen D. Streptozocin-doxorubicin, streptozocin-fluorouracil or chlorozotocin in the treatment of advanced islet-cell carcinoma. N Engl J Med. 1992;326:519-23.
45. Cheng P, Saltz L. Failure to confirm major objective antitumor activity for streptozocin and doxorubicin in the treatment of patients with advanced islet cell carcinoma. Cancer. 1999;86:944-8.
46. Kouvaraki MA, Ajani JA, Hoff P, et al. Fluorouracil, doxorubicin, and streptozocin in the treatment of patients with locally advanced and metastatic pancreatic endocrine carcinomas. J Clin Oncol. 2004;22:4762-71.
47. Ramanathan R, Cnaan A, Hahn R, et al. Phase II trial of dacarbazine (DTIC) in advanced pancreatic islet cell carcinoma. Study of the Eastern Cooperative Oncology Group-E6282. Ann Oncol. 2001;12:1139-43.
48. Kulke M, Stuart K, Enzinger P, et al. Phase II study of temozolomide and thalidomide in patients with metastatic neuroendocrine tumors. J Clin Oncol. 2006;24:401-6.
49. Varker KA, Campbell J, Shah MH. Phase II study of thalidomide in patients with metastatic carcinoid and islet cell tumors. Cancer Chemother Pharmacol. 2008;61:661-8.
50. Ekeblad S, Sundin A, Janson ET, et al. Temozolomide as monotherapy is effective in treatment of advanced malignant neuroendocrine tumors. Clin Cancer Res. 2007;13:2986-91.
51. Strosberg JR, Fine RL, Choi J, et al. First-line chemotherapy with capecitabine and temozolomide in patients with metastatic pancreatic endocrine carcinomas. Cancer. 2011;117:268-75.
52. Cassier PA,Walter T, Eymard B, et al. Gemcitabine and oxaliplatin combination chemotherapy for metastatic well-differentiated neuroendocrine carcinomas: A single-center experience. Cancer. 2009;115:3392-9.
53. Bajetta E, Catena L, Procopio G, et al. Are capecitabine and oxaliplatin (XELOX) suitable treatments for progressing lowgrade and high-grade neuroendocrine tumours? Cancer Chemother Pharmacol. 2007;59:637-42.
54. Bergsland E, Ko A, Tempero M, et al. Phase II trial of FOLFOX plus bevacizumab in advanced, progressive neuroendocrine tumors (abstract 216). Data presented at the 2008 ASCO Gastrointestinal Cancers Symposium, Orlando, FL 2008; http://www.asco.org/ ASCOv2/Meetings/Abstracts?&vmview0abst-detail- view&confID053&abstractID010380
55. Kunz P, Kuo T, Zahn J, et al. A phase II study of capecitabine, oxaliplatin, and bevacizumab for metastatic or unresectable neuroendocrine tumors (abstract 4104). J Clin Oncol 2010;28:326s Abstract available online at http://www.asco.org/ASCOv2/ Meetings/Abstracts?&vmview0abst-detail- view&confID074& abstractID054381 (Accessed on February 10, 2011).
56. Kulke M, Frauenhoffer C, Hooshmand D, Ryan P, et al. Prediction of response to temozolamide (TMZ)-based therapy by loss of MGMT expression in patients with advanced neuroendocrine tumors (NET). In: Proceedings ASCO; 2007; Chicago, IL; 2007.
57. Moertel C, Hanley J. Combination chemotherapy trials in metastatic carcinoid tumor and the malignant carcinoid syndrome. Cancer Clin Trials. 1979;2:327-34.
58. Engstrom P, Lavin P, Moertel CG, et al. Streptozocin plus fluorouracil versus doxorubicin therapy for metastatic carcinoid tumor. J Clin Oncol. 1984;2:1255-59.
59. Bukowski R, Johnson K, Peterson R, et al. A phase II trial of combination chemotherapy in patients with metastatic carcinoid tumors. A Southwest Oncology Group Study. Cancer. 1987;60:2891-5.
60. Sun W, Lipsitz S, Catalano P, et al. Phase II/III study of doxorubicin with fluorouracil compared with streptozocin with fluorouracil or dacarbazine in teh treatment of advanced carcinoid tumors: Eastern Cooperative Oncology Group Study E1281. J Clin Oncol. 2005;23:4897-904.